NeenaH
@NeenaHaider
Followers
389
Following
493
Media
12
Statuses
2K
#mom #genetherapy #precisionmedicine #curingblindness #thisisharvardmecicine #friend we are made of stardust. believe in your magic and anything is possible 💗
Boston
Joined October 2011
#healthcare #PrecisionMedicine I’m starting a heathcare company https://t.co/WAANAshMJy excited to be discussing our platform @TEDxMB!
0
0
9
Excited to announce that I will be giving a talk at TEDxManhattanBeach November 15, 2025! Join me at Mira Costa High School for a day of unstoppable ideas worth spreading. Tickets on sale now— https://t.co/4ifdtrwey3 hope to see you there!#TEDxManhattanBeach #TEDx #Unstoppable
tedxmanhattanbeach.org
0
2
14
The Ocu400 and 410 platforms are the therapies I invented. It’s beyond words to see how many people we are helping!
$OCGN Let there be light… and colors for everyone. @DrMakaryFDA
@Ocugen #ocugen #OCU400 #Neocart #RHO #NR2E3 #PDE6B #BLA #MAA #Ophthalmology @NeenaHaider @drhumaqamar
5
17
79
Breaking: a group of current and former OpenAI employees is speaking out about what they say is a culture of recklessness and secrecy at the company. They are asking for a “right to warn” for employees of frontier AI labs.
22
149
496
https://t.co/1mMNQVxnUT Exciting preclinical study is now out! @genetherapy_SN This informed the FDA approved clinical trials. Thank you to our amazing team and @macular_org @Ocugen #curingblindness #stargardt #genetherapy
link.springer.com
Gene Therapy - Degeneration of the macula is associated with several overlapping diseases including age-related macular degeneration (AMD) and Stargardt Disease (STGD). Mutations in ATP Binding...
3
18
76
How profound and exciting to see my work come to fruition! One step closer to bring this to everybody who needs it! Congratulations to my team for the last 20 years and to Ocugen for moving it forward through the clinic!!
Ocugen announces U.S. FDA clearance of IND amendment to initiate OCU400 Phase 3 (liMeliGhT) Clinical Trial--the first gene therapy to enter Phase 3 with a broad retinitis pigmentosa indication. For more information, read the full press release here. https://t.co/KXTZWsQALm
0
28
102
My second gene therapy to clinic! In on a roll! More amazing things to come! Stay tuned!
Yesterday, Ocugen announced the positive data and safety monitoring board review and initiation of enrollment for OCU410ST Medium Dose Cohort, a modifier gene therapy study for Stargardt disease. For more details, see the full press release here. https://t.co/wHzwTsMXw1
0
19
84
0
0
1
Excited to see this! My second gene therapy!
Today, Ocugen announced the completion of dosing in the first cohort of the Phase 1/2 ArMaDa clinical trial for OCU410, a modifier gene therapy candidate being developed for geographic atrophy. For more details, https://t.co/uM0ZJMtU90
#ga #dAMD @macular_org @NeenaHaider
5
24
84
This is the second gene therapy I developed!! #genetherapy my preclinical work funded by @Ocugen and @macular_org !!
Ocugen’s first-in-class modifier gene therapy platform, and its potential to treat dry AMD, highlighted in @EpochTimes
https://t.co/FRrA4sVtw0 (subscription required)
2
18
71
Another milestone step forward in this incredible journey!
.@Ocugen and the FDA have agreed on trial design aspects including end point, patient enrollment strategy, and study duration. #RetinitisPigmentosa #GeneTherapy
https://t.co/YjrALQG4iq
1
13
55
Just Do It!
This is the year to be the boldest, most courageous version of yourself.
0
0
16
His Holiness’ Message for the New Year - 2024 On the occasion of the New Year, I would like to thank everyone who has sent me good wishes, and I offer my greetings to you all, brothers and sisters across the world. Despite the many challenges that we are facing today, I feel
575
2K
8K
Moving forward! Closer to our goal of preventing and/or restoring vision loss for these patients.
Ocugen Gains FDA Alignment on Key Aspects of #OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design #Ocugen $OCGN 🧬 https://t.co/dQKWGiFX7M
1
12
64
$OCGN A villager appreciation of your hard work @NeenaHaider For us long time investors, we saw a brighter future for the world through @Ocugen visions. It’s a tough road but like many amazing technology delivered to the world, it needed time, commitment and a team. We got
@NeenaHaider I appreciate your tireless commitment and hard work. Your dedication, evident in the sacrifices made during years of research and long lab days, is truly commendable. Your brilliant contributions bring hope to many, Thank you.
2
7
26
Thank you, American Macular Degeneration Foundation for highlighting the potential for OCU410 and the pioneering work of Dr. Neena Haider among your membership. To read more, click here: https://t.co/Rd8tZMMcQD
1
12
51
Moving towards the shared goal of helping people! This is the first therapy I developed. We are transforming healthcare! @NIH @NatEyeInstitute @Ocugen @macular_org @PeteSessions_AP
instagram.com
2
5
21
How exciting to see my preclinical work, second gene therapy!, coming to the clinic now to treat #dryAMD thank you to @Ocugen @macular_org and everyone supporting this exciting innovative platform!
.@Ocugen announced that the first patient has been dosed in the ArMaDa phase 1/2 clinical trial of OCU410 (AAV-RORA), a modifier gene therapy product candidate being developed for #dryAMD (AMD). https://t.co/p4MNJR0uRT
2
22
94
Are you or someone you know affected by Retinitis Pigmentosa (RP)/Leber Congenital Amaurosis (LCA)? Ocugen is currently conducting a Natural History Study. Please visit https://t.co/UZ5qdUCvlG (NCT05203939) for more information.
0
16
61